Similar articles

• Influence of diphenylhydantoin on electrophysiological properties of the canine heart.

  Rosati RA, Alexander JA, Schaal SF, Wallace AG. Rosati RA, et al. Circ Res. 1967 Nov;21(5):757-65. doi: 10.1161/01.res.21.5.757. Circ Res. 1967. PMID: 6073567 No abstract available.
• Depression of cardiac sympathetic nerve activity by diphenylhydantoin.

  Gillis RA, McClellan JR, Sauer TS, Standaert FG. Gillis RA, et al. J Pharmacol Exp Ther. 1971 Dec;179(3):599-610. J Pharmacol Exp Ther. 1971. PMID: 5138030 No abstract available.
• Some cardiovascular effects of germine-3-monoacetate.

  Scriabine A, Stavorski JM, Ludden CT, Stone CA. Scriabine A, et al. Eur J Pharmacol. 1971 May;14(4):313-8. doi: 10.1016/0014-2999(71)90184-1. Eur J Pharmacol. 1971. PMID: 5157763 No abstract available.
• Diphenylhydantoin as an antiarrhythmic drug.

  Atkinson AJ Jr, Davison R. Atkinson AJ Jr, et al. Annu Rev Med. 1974;25:99-113. doi: 10.1146/annurev.me.25.020174.000531. Annu Rev Med. 1974. PMID: 4596238 Review. No abstract available.
• The current status of diphenylhydantoin in heart disease.

  Mercer EN, Osborne JA. Mercer EN, et al. Ann Intern Med. 1967 Nov;67(5):1084-107. doi: 10.7326/0003-4819-67-5-1084. Ann Intern Med. 1967. PMID: 4860765 Review. No abstract available.